RPRX Royalty Pharma plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RPRX

Price (delayed)

$28.76

Market cap

$17.18B

P/E Ratio

73.74

Dividend/share

$0.8

EPS

$0.39

Enterprise value

$22.38B

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals ...

Highlights
The P/E is 48% lower than the last 4 quarters average of 142.3
Royalty Pharma's debt has decreased by 14% QoQ and by 14% YoY
Royalty Pharma's EPS has shrunk by 66% YoY and by 29% QoQ
The net income has plunged by 64% YoY and by 28% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.royaltypharma.com
Peers: ANIP ABT LLY

Key stats

What are the main financial stats of RPRX
Market
Shares outstanding
597.43M
Market cap
$17.18B
Enterprise value
$22.38B
Valuations
Price to earnings (P/E)
73.74
Price to book (P/B)
1.81
Price to sales (P/S)
5.55
EV/EBIT
60.27
EV/EBITDA
60.27
EV/Sales
9.63
Earnings
Revenue
$2.32B
EBIT
$371.3M
EBITDA
$371.3M
Free cash flow
$2.77B
Per share
EPS
$0.39
Free cash flow per share
$6.18
Book value per share
$15.93
Revenue per share
$5.18
TBVPS
$35.36
Balance sheet
Total assets
$15.86B
Total liabilities
$6.27B
Debt
$6.13B
Equity
$9.59B
Working capital
$1.6B
Liquidity
Debt to equity
0.64
Current ratio
13.51
Quick ratio
13.46
Net debt/EBITDA
13.99
Margins
EBITDA margin
16%
Gross margin
100%
Net margin
7.9%
Operating margin
17.1%
Efficiency
Return on assets
1.1%
Return on equity
1.9%
Return on invested capital
1.8%
Return on capital employed
2.4%
Return on sales
16%
Dividend
Dividend yield
2.78%
DPS
$0.8
Payout ratio
205.1%

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
1.09%
1 week
6.91%
1 month
3.53%
1 year
-31.41%
YTD
-27.23%
QTD
5.97%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.32B
Gross profit
$2.32B
Operating income
$396.6M
Net income
$184.41M
Gross margin
100%
Net margin
7.9%
Royalty Pharma's net margin has shrunk by 65% YoY and by 27% QoQ
The net income has plunged by 64% YoY and by 28% from the previous quarter
The operating margin has dropped by 59% year-on-year and by 8% since the previous quarter
The operating income has plunged by 58% YoY and by 9% from the previous quarter

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
RPRX P/E details
P/E
73.74
P/B
1.81
P/S
5.55
EV/EBIT
60.27
EV/EBITDA
60.27
EV/Sales
9.63
Royalty Pharma's EPS has shrunk by 66% YoY and by 29% QoQ
The P/E is 48% lower than the last 4 quarters average of 142.3
RPRX's P/B is 14% below its last 4 quarters average of 2.1
RPRX's equity is down by 8% year-on-year and by 2.3% since the previous quarter
The P/S is 13% below the last 4 quarters average of 6.4
The revenue has increased by 3.4% YoY

Efficiency

How efficient is Royalty Pharma business performance
The ROA has plunged by 62% YoY and by 27% from the previous quarter
RPRX's ROE has plunged by 61% YoY and by 27% from the previous quarter
Royalty Pharma's return on sales has decreased by 48% YoY and by 15% QoQ
The ROIC is down by 42% YoY and by 14% QoQ

Dividends

What is RPRX's dividend history
Dividend details
DPS
$0.8
Dividend yield
2.78%
Payout ratio
205.1%
Recent dividends

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 153% more than its total liabilities
The total liabilities has declined by 14% since the previous quarter and by 14% year-on-year
Royalty Pharma's total assets has decreased by 10% YoY and by 7% from the previous quarter
Royalty Pharma's debt is 36% lower than its equity
Royalty Pharma's debt has decreased by 14% QoQ and by 14% YoY
The debt to equity has decreased by 12% QoQ and by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.